美国 · SEC FORM 4
Scholar Rock Holding Corp
SRRK · Nasdaq · CIK 0001727196 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
26 同一窗口内观察到的 Form 4 交易行
13 sales · 13 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-10-07 · AKKARAJU SRINIVAS · $1.2M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Burow KristinaDirector
○○▼
FLIER JEFFREY S.Director
○▼
Reed JoshuaDirector
○▼
Gilman MichaelDirector
○▼
Peng KatieDirector
○▼
Brudnick RichardDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-10-07 · AKKARAJU SRINIVAS.
近期 Form 4 活动
0买入
38卖出
35其他 Form 4 交易行
46SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出13 sale line(s) · 仅供背景
其他13 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 22,722,119
- 上期报告
- 19,407,706
- 日均成交量
- 2,437,734
- 回补天数
- 9.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-10-07 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 29,599 | USD 39.92 | USD 1,181,634 | SEC 申报 ↗ |
| 2025-10-06 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 113,025 | USD 38.65 | USD 4,368,808 | SEC 申报 ↗ |
| 2025-10-03 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 387,414 | USD 37.27 | USD 14,438,544 | SEC 申报 ↗ |
| 2023-10-16 | Samsara BioCapital GP, LLC; Samsara BioCapital, L.P. | 买入 (P) | Common Stock | 2,189,781 | USD 6.85 | USD 15,000,000 | SEC 申报 ↗ |
| 2023-10-16 | AKKARAJU SRINIVAS | 买入 (P) | Common Stock | 2,189,781 | USD 6.85 | USD 15,000,000 | SEC 申报 ↗ |
| 2023-10-12 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 2,199,931 | USD 6.86 | USD 15,086,782 | SEC 申报 ↗ |
| 2023-04-28 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 31,557 | USD 6.43 | USD 202,912 | SEC 申报 ↗ |
| 2023-01-05 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 48,774 | USD 9.33 | USD 455,061 | SEC 申报 ↗ |
| 2022-10-25 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 130,265 | USD 8.04 | USD 1,047,331 | SEC 申报 ↗ |
| 2022-10-04 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 66,000 | USD 7.89 | USD 520,740 | SEC 申报 ↗ |
| 2022-10-03 | Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Westend S.A.; Wittouck Amaury | 买入 (P) | Common Stock | 33,971 | USD 7.03 | USD 238,816 | SEC 申报 ↗ |
| 2022-06-22 | Nashat Amir | 买入 (P) | Common Stock | 1,197,992 | USD 4.90 | USD 5,870,161 | SEC 申报 ↗ |
Form 4 申报证据
73 transaction lines in the latest 365-day window; 352 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Woods Keith | 赠与 (G) | Common Stock | 48,034 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-21 | Hallal David | 赠与 (G) | Common Stock | 36,652 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-01 | Reed Joshua | 卖出 (S) | Common Stock | 3,053 | USD 53.74 | USD 164,075 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Woods Keith | 赠与 (G) | Common Stock | 48,034 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-21 | Hallal David | 赠与 (G) | Common Stock | 36,652 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-01 | Reed Joshua | 卖出 (S) | Common Stock | 3,053 | USD 53.74 | USD 164,075 | SEC 申报 ↗ |
| 2026-07-01 | Peng Katie | 卖出 (S) | Common Stock | 5,446 | USD 53.87 | USD 293,399 | SEC 申报 ↗ |
| 2026-07-01 | Gilman Michael | 卖出 (S) | Common Stock | 2,544 | USD 53.87 | USD 137,057 | SEC 申报 ↗ |
| 2026-07-01 | FLIER JEFFREY S. | 卖出 (S) | Common Stock | 3,053 | USD 53.88 | USD 164,491 | SEC 申报 ↗ |
| 2026-07-01 | Burow Kristina | 卖出 (S) | Common Stock | 3,053 | USD 53.74 | USD 164,054 | SEC 申报 ↗ |
| 2026-06-04 | Reed Joshua | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Peng Katie | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Gilman Michael | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | FLIER JEFFREY S. | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Burow Kristina | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | Brudnick Richard | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-04 | AKKARAJU SRINIVAS | 奖励／授予 (A) | Common Stock | 6,839 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-23 | Burow Kristina | 期权行权／转换 (M) | Common Stock | 89,800 | USD 9.14 | USD 820,324 | SEC 申报 ↗ |
| 2026-04-16 | Woods Keith | 卖出 (S) | Common Stock | 10,220 | USD 49.57 | USD 506,605 | SEC 申报 ↗ |
| 2026-04-16 | Vaishnaw Akshay | 卖出 (S) | Common Stock | 12,246 | USD 49.57 | USD 607,034 | SEC 申报 ↗ |
| 2026-04-16 | Sinha Vikas | 卖出 (S) | Common Stock | 10,410 | USD 49.57 | USD 516,024 | SEC 申报 ↗ |
| 2026-04-16 | Hallal David | 卖出 (S) | Common Stock | 30,615 | USD 49.57 | USD 1,517,586 | SEC 申报 ↗ |
| 2026-02-23 | Qatanani Mo | 卖出 (S) | Common Stock | 8,484 | USD 47.07 | USD 399,335 | SEC 申报 ↗ |
| 2026-02-17 | Qatanani Mo | 卖出 (S) | Common Stock | 7,989 | USD 46.53 | USD 371,728 | SEC 申报 ↗ |
| 2026-02-17 | Parlavecchio Caryn | 卖出 (S) | Common Stock | 9,035 | USD 46.53 | USD 420,399 | SEC 申报 ↗ |
| 2026-02-17 | Marantz Jing L. | 卖出 (S) | Common Stock | 4,157 | USD 46.53 | USD 193,425 | SEC 申报 ↗ |
| 2026-02-17 | Ho Junlin | 卖出 (S) | Common Stock | 9,580 | USD 46.53 | USD 445,757 | SEC 申报 ↗ |
| 2026-02-09 | Woods Keith | 奖励／授予 (A) | Common Stock | 47,021 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | Vaishnaw Akshay | 奖励／授予 (A) | Common Stock | 47,021 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | Sinha Vikas | 奖励／授予 (A) | Common Stock | 47,021 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | Qatanani Mo | 奖励／授予 (A) | Common Stock | 29,258 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | Parlavecchio Caryn | 奖励／授予 (A) | Common Stock | 29,258 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-09 | Marantz Jing L. | 奖励／授予 (A) | Common Stock | 34,482 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SRRK |
| CIK | 0001727196 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 352 transaction lines from 2020-11-23 to 2026-09-24 20 P purchase lines · 161 S sale lines · 171 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.